Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Observational 3Interventional 2

Sponsor

Conditions

Breast Neoplasms 4997Neoplasms 4192Prostatic Neoplasms 2426Carcinoma, Non-Small-Cell Lung 2261Colorectal Neoplasms 2050Lung Neoplasms 1703Multiple Myeloma 1454Lymphoma 1403Leukemia, Myeloid, Acute 1379Neoplasm Metastasis 1372Melanoma 1269Pancreatic Neoplasms 1200Leukemia 1194Ovarian Neoplasms 1190Lymphoma, Non-Hodgkin 1128Precursor Cell Lymphoblastic Leukemia-Lymphoma 1088Head and Neck Neoplasms 1055Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 896Colonic Neoplasms 893Brain Neoplasms 875Stomach Neoplasms 854Recurrence 848Carcinoma, Hepatocellular 845Glioblastoma 837Lymphoma, Large B-Cell, Diffuse 770Rectal Neoplasms 758Uterine Cervical Neoplasms 725Carcinoma, Renal Cell 704Hodgkin Disease 696

Interventions

ropinirole 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Hyperprolactinemia × Clear all
NCT00914823 2024-07-31

Kisspeptin Administration in the Adult

Massachusetts General Hospital

Phase 1 Completed
256 enrolled

Hyperprolactinemia, Hypogonadism, Polycystic Ovary Syndrome, Kallmann Syndrome

NCT03038308 2024-06-04

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Columbia University

Phase 1/2 Completed
16 enrolled 8 charts

Hyperprolactinemia, Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡